0.83 is Celgene Corp’s (NASDAQ:CELG) Big Money Sentiment

May 17, 2018 - By Matthew Richard

Celgene Corporation (NASDAQ:CELG) Corporate Logo

Celgene Corp’s Sentiment

“Big money sentiment for Celgene Corp (NASDAQ:CELG) in Q4 2017 decreased to 0.83, SEC.gov filings reveal. So its down -0.34, from 2017Q3’s 1.17. 529 institutional investors increased or opened new holdings, while 634 sold and reduced their equity positions in Celgene Corp so the sentiment turned negative. These funds own 561.38 million shares, that’s down from 603.99 million shares in 2017Q3. Funds holding Celgene Corp in top 10 decreased from 119 to 38 for a decrease of 81. 156 Investors Sold All; 478 Reduced Holdings; 411 increased holdings while 118 institutional investors bought holdings.

Largest Celgene Corp Shareholders

Birchview Capital Lp owns 744,051 shares in Celgene Corp as of Q4 2017. Celgene Corp’s shareholder Oaktop Capital Management Ii L.P. owns 2.11 million shares as of Q4 2017. Moreover, Selkirk Management Llc reported 260,000 shares in Celgene Corp equivalent to 14.49% of its equity exposure. Bb Biotech Ag revealed 3.42 million shares position in Celgene Corp. The United Kingdom-based fund Edinburgh Partners Ltd holds 315,906 shares or 8.7% of their equity exposure.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The firm is worth $59.09 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.22.35 is the P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Ticker’s shares touched $81.36 during the last trading session after 0.76% change.Celgene Corporation has volume of 6.04M shares. Since May 17, 2017 CELG has declined 31.28% and is downtrending. CELG underperformed by 42.83% the S&P 500.

Earnings report for Celgene Corporation (NASDAQ:CELG) is anticipated on July, 26., RTT reports. Analysts expect change of 11.31 % or $0.19 from previous year’s $1.68 earnings per share compared to current’s $1.87 earnings per share. In case of $1.87 earnings per share CELG’s profit could be $1.36B. Last quarter $1.61 earnings per share was reported. Analysts predicts 16.15 % EPS growth this quarter.

Robeco Institutional Asset Management Bv owns 0.04% invested in Celgene Corporation (NASDAQ:CELG) for 71,073 shs. Investment House Ltd Liability Corp holds 0.92% or 72,411 shs in its capital. Intrust Bank & Trust Na has invested 0.31% in Celgene Corporation (NASDAQ:CELG). Wolverine Asset Mngmt Lc stated it has 0.01% in Celgene Corporation (NASDAQ:CELG). Ngam Advsrs Ltd Partnership holds 170,115 shs. Parsons Management Ri invested in 48,947 shs or 0.57% of the stock. Ally Financial Inc has 0.4% invested in Celgene Corporation (NASDAQ:CELG). Waldron Limited Partnership owns 3,498 shs. Jefferies Gp Ltd Limited Liability Company has invested 0% in Celgene Corporation (NASDAQ:CELG). Jacobs Levy Equity Management, New Jersey-based fund reported 251,753 shs. At Natl Bank stated it has 0.3% of its capital in Celgene Corporation (NASDAQ:CELG). Davis R M reported 0.01% of its capital in Celgene Corporation (NASDAQ:CELG). Anchor Capital Advsrs owns 0.01% invested in Celgene Corporation (NASDAQ:CELG) for 2,300 shs. Eulav Asset Management reported 207,000 shs. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.32% or 342,640 shs in its capital.

Celgene Corporation registered $3.58 million net activity with 1 insider buy and 3 selling transactions since February 8, 2018. Alles Mark J had bought 3,260 shs worth $299,594. Another trade for 9,250 shs valued at $851,093 was made by LOUGHLIN JAMES J on Monday, March 12. KAPLAN GILLA had sold 18,500 shs worth $1.77M.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

A total of 20 analysts rate Celgene (NASDAQ:CELG) as follows: 13 “Buy”, 7 “Hold” and 0 “Sell”. Тherefore 65% are bullish. The firm has $152.0 highest and $90 lowest target. The avg target $122 is 49.95% above the last ($81.36) price. (NASDAQ:CELG) has 35 ratings reports on 17 May 2018 according to StockzIntelligence. On Thursday, January 25 the rating was maintained by SunTrust with “Buy”. On Wednesday, February 28 the rating was maintained by Credit Suisse with “Outperform”. In Wednesday, February 28 report Stifel Nicolaus maintained it with “Buy” rating and $128 target. On Wednesday, February 28 BMO Capital Markets maintained Celgene Corporation (NASDAQ:CELG) with “Outperform” rating. On Wednesday, December 27 the firm has “Market Perform” rating by Bernstein given. On Wednesday, December 13 Leerink Swann maintained Celgene Corporation (NASDAQ:CELG) with “Buy” rating. The company rating was maintained by Canaccord Genuity on Tuesday, January 23. On Thursday, December 21 the rating was maintained by Piper Jaffray with “Hold”. On Tuesday, February 13 the company was upgraded by Barclays Capital. On Monday, February 5 the firm has “Buy” rating by Mizuho given.

For more Celgene Corporation (NASDAQ:CELG) news brought out recently go to: Seekingalpha.com, Seekingalpha.com, Fool.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Celgene’s (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)” brought out on May 16, 2018, “Celgene Earnings Preview” on April 30, 2018, “Celgene Starts the Year With a Bang” with a publish date: May 14, 2018, “My 2 Cents On The Ozanimod Saga” and the last “Nohla Therapeutics Announces Closing of $45 Million Series B Financing” with publication date: May 15, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: